Angioimmunoblastic T-cell lymphoma

It is a cancer of T follicular helper cells — the T cells whose normal job is helping B cells make antibodies. That origin explains a great deal about how the illness behaves, because the cells that go wrong are the ones that normally regulate an immune response.

The name has changed and both names are still in use. The World Health Organization’s current classification files this disease inside a group called nodal T-follicular helper cell lymphoma, alongside two related entities. If you were diagnosed under the older name, or the newer one, you are in the right place.

The NCI describes it as the most common of the entities in that group and the second most common peripheral T-cell lymphoma overall.

It is uncommon. Cancer Research UK puts UK diagnoses at around 140 people a year, typically around age 70. Lymphoma Action gives around 250 a year for the broader group it now sits inside — those two are not in conflict, they are counting different boundaries.

Cancer Research UK names no specific cause or risk factor, and that is the accurate answer rather than a gap in our reading.

Lymphoma Action notes a link with two common viruses — Epstein-Barr virus and human herpesvirus 6 — while stating that whether they cause it remains unclear. That distinction is worth holding onto. Epstein-Barr virus in particular is extremely common in the general population, and a past glandular fever infection does not explain this diagnosis.

None of the sources we read describes an inherited cause, a lifestyle cause or an environmental exposure.

People typically present with widespread swollen lymph nodes, fever, night sweats, weight loss and a skin rash.

What sets this lymphoma apart is that it disorders the immune system itself. Two findings the NCI lists say it plainly: a positive Coombs test, meaning antibodies are attacking the person’s own red blood cells, and an excess of antibody protein in the blood. Those are signs of an immune system thrown into disarray by the lymphoma, not of an infection.

Lymphoma Action adds an enlarged liver and spleen causing abdominal discomfort, itching and rash, marrow involvement causing anemia and low platelets, and autoimmune reactions affecting blood cells, joints and the thyroid.

It is usually advanced when it is found. In the largest review of these cases, 89% had stage III or IV disease at diagnosis, with widespread node enlargement in 76%.

That combination — feeling systemically unwell, an immune system attacking the body, and only then a lymphoma diagnosis — is why people often describe having been investigated for something else first.

First-line treatment is combination chemotherapy, at the same doses used for the common fast-growing B-cell lymphoma.

Where the lymphoma cells display a protein called CD30, one targeted drug can replace part of that chemotherapy: brentuximab vedotin, an antibody carrying a cell-killing drug that it delivers into CD30-bearing cells. Whether it is an option depends on a test done on the biopsy, so it is not automatic here.

Rituximab is sometimes added, and it is worth understanding why, because it is easy to misread. Rituximab targets a marker found on B cells, not T cells. It is given because of an accompanying expanded B-cell population that this lymphoma tends to drive — not because it treats the T-cell lymphoma itself.

For people who reach a first complete remission, a transplant using their own cells may be offered as consolidation.

How strong that recommendation is depends on where you look, and the honest answer is that it is not settled. EBMT’s own table grades a first-remission transplant here as a clinical option to be weighed case by case, rather than as something generally indicated. The NCI describes the evidence behind it as anecdotal, drawn from small and backward-looking studies rather than from a trial designed to answer the question.

CAR T-cell therapy is graded as generally not recommended for this group of lymphomas at every stage of disease.

The immune disorder is part of the illness rather than only a consequence of treatment. Autoimmune attacks on red cells, joints and the thyroid, and a raised risk of infection, appear in the sources as features of the disease itself.

Diagnosis needs a lymph node biopsy with laboratory staining, and CD30 status is one of the things that decides which drugs are available.

Treatment runs as multiple cycles of chemotherapy.

If consolidation is planned, stem cells are collected from the bloodstream in advance, high-dose chemotherapy follows, and the stored cells are returned. It means an inpatient stay with very low blood counts, and no donor search.

None of the sources we read reports on quality of life, diagnostic delay or fertility for this condition. We would rather name that gap than fill it.

On the path most people with this diagnosis are on, a donor plays no part. The transplant discussed after a first remission uses the person’s own cells, and EBMT states that a donor transplant is not an indication as first-line consolidation for this group of lymphomas.

It becomes relevant later. If the lymphoma comes back and responds to further treatment, a transplant from a matched sibling or a well-matched unrelated donor is graded as generally indicated in suitable people, and EBMT describes a donor transplant as the one treatment able to cure people whose disease is refractory or has relapsed, where they are fit enough for it.

A donor transplant is not a safer or gentler option than the alternative, and it would be dishonest of us to imply it. In a randomised trial of 104 people with this group of lymphomas, 31% of those who had a donor transplant died of graft-versus-host disease — the donor’s immune cells attacking the recipient’s own tissues. The NCI’s summary of that trial is that the benefit of the donor immune system attacking the lymphoma was cancelled out by deaths from the transplant itself.

So the honest registry case here is narrow: it is for the minority whose disease relapses or does not respond, and it is not something anyone needs to act on at diagnosis.